RUNX1 and myeloid neoplasm: The genome-first UK BioBank cohort study reported deleterious germline RUNX1 alleles increase the risk of HMs in general (odds ratio 66) and myeloid malignancies (odds ratio 210) in particular (p ≤ 0.001) [29].